Grey Matters Retains Nationally Recognized ProScan to Read Brain Images from its Flagship NovaScan Neuroimaging Clinics™ Location in Florida

Article content

U.S. Flagship – NovaScan Neuroimaging Clinics^TM

Article content

The inaugural NovaScan Neuroimaging Clinics^TM location is at the HCA Florida University Medical Office Building in Davie, located on the campus of the HCA Florida University Hospital, and will be the first of its kind in the U.S. to provide brain dedicated PET scans to aid in the detection of Alzheimer’s Disease (AD) and other forms of neurodegenerative diseases including frontotemporal dementia, Parkinson’s, and Lewy Body Dementia, and will be additionally used for other select neuro-oncology applications.

Article content

Article content

Article content

Article content

HCA Florida University Medical Office Building / Davie, Florida

Article content

Brain PET scans for beta-amyloid plaque detection (associated with advancing AD) are covered by Medicare, Medicaid and private insurance for those 65+, with patients being referred to NovaScan Neuroimaging Clinics^TM by Neurologists, Geriatricians, and Primary Care Physicians. The clinic will feature the U.S. FDA-cleared CareMiBrain™ system, a ground-breaking, new seated diagnostic brain PET scanner, that does not need an integrated Computed Tomography (CT) component to produce high quality images, resulting in 25% less radiation exposure for patients.

Article content

Article content

Article content

Article content

Article content

The CareMiBrain^TM PET Brain Scanning System

Article content

There are two recently U.S. FDA approved monoclonal antibody treatments for AD, which are also covered by Medicare, Medicaid and private insurance, designed to slow the progression of the disease – Leqembi (Eisai and Biogen) and Kisunla (Eli Lilly) – and both require a positive beta-amyloid brain scan (or spinal tap) in order for patients to be authorized to receive them. These drugs can dissolve amyloid plaque build-up in the brain and slow the progression of a patient’s cognitive decline, and have helped create a billion-dollar market opportunity for the brain specific PET scan and AD treatment space.

Article content

The United States’ current supply of PET scanners – the majority being a PET/CT hybrid technology – is vastly insufficient to serve the massive new market emerging for AD diagnostics and treatment. The majority of PET/CT scanners, 45% of which are located in hospitals, are primarily prioritized as cancer diagnostic and theranostic tools, and for cardiac imaging, which can make it challenging to schedule brain-specific scans on a timely basis.

Article content

Article content

The Grey Matters Health business plan is to open a national chain of its NovaScan Neuroimaging Clinics^TM throughout the U.S.

Article content

For more information please contact:

Article content

Christopher J. Moreau
CEO
Grey Matters Health Inc.
604.398.4175 Ext 701

Article content

Article content

About Grey Matters  

Article content

Grey Matters is a Canadian healthcare company focused on the provision of brain dedicated PET scanning services through a planned network of new neuroimaging clinics in the U.S. for the early-stage detection of Alzheimer’s Disease and other forms of neurodegenerative diseases, including frontotemporal dementia, Parkinson’s, and Lewy body dementia, and will additionally offer other select neuro-oncology imaging applications too.

Article content

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Article content

CAUTIONARY DISCLAIMER STATEMENT: This news release contains forward-looking statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Article content

Photos accompanying this announcement are available at: 

Article content

Article content

Article content

Article content

Article content

Article content

Article content

Article content